{
  "DOI": "10.1038/s41431-020-0612-1",
  "ISSN": [
    "1018-4813",
    "1476-5438"
  ],
  "URL": "http://dx.doi.org/10.1038/s41431-020-0612-1",
  "abstract": "\u003cjats:title\u003eAbstract\u003c/jats:title\u003e\u003cjats:p\u003eRare sequence variants in the non-coding part of the \u003cjats:italic\u003eBRCA\u003c/jats:italic\u003e genes are often reported as variants of uncertain significance (VUS), which leave patients and doctors in a challenging position. The aim of this study was to determine the pathogenicity of the \u003cjats:italic\u003eBRCA1\u003c/jats:italic\u003e c.5407-25T\u0026gt;A variant found in 20 families from Norway, France and United States with suspected hereditary breast and ovarian cancer. This was done by combining clinical and family information with allele frequency data, and assessment of the variant’s effect on mRNA splicing. Mean age at breast (\u003cjats:italic\u003en\u003c/jats:italic\u003e = 12) and ovarian (\u003cjats:italic\u003en\u003c/jats:italic\u003e = 11) cancer diagnosis in female carriers was 49.9 and 60.4 years, respectively. The mean Manchester score in the 20 families was 16.4. The allele frequency of \u003cjats:italic\u003eBRCA1\u003c/jats:italic\u003e c.5407-25T\u0026gt;A was 1/64,566 in non-Finnish Europeans (gnomAD database v2.1.1). We found the variant in 1/400 anonymous Norwegian blood donors and 0/784 in-house exomes. Sequencing of patient-derived cDNA from blood, normal breast and ovarian tissue showed that \u003cjats:italic\u003eBRCA1\u003c/jats:italic\u003e c.5407-25T\u0026gt;A leads to skipping of exon 23, resulting in frameshift and protein truncation: p.(Gly1803GlnfsTer11). Western blot analysis of transiently expressed BRCA1 proteins in HeLa cells showed a reduced amount of the truncated protein compared with wild type. Noteworthily, we found that a small amount of full-length transcript was also generated from the c.5407-25T\u0026gt;A allele, potentially explaining the intermediate cancer burden in families carrying this variant. In summary, our results show that \u003cjats:italic\u003eBRCA1\u003c/jats:italic\u003e c.5407-25T\u0026gt;A leads to partial skipping of exon 23, and could represent a likely pathogenic variant with reduced penetrance.\u003c/jats:p\u003e",
  "alternative-id": [
    "612"
  ],
  "assertion": [
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Received",
      "name": "received",
      "order": 1,
      "value": "16 October 2019"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Revised",
      "name": "revised",
      "order": 2,
      "value": "3 March 2020"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "Accepted",
      "name": "accepted",
      "order": 3,
      "value": "10 March 2020"
    },
    {
      "group": {
        "label": "Article History",
        "name": "ArticleHistory"
      },
      "label": "First Online",
      "name": "first_online",
      "order": 4,
      "value": "20 March 2020"
    },
    {
      "group": {
        "label": "Compliance with ethical standards",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 1
    },
    {
      "group": {
        "label": "Conflict of interest",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 2,
      "value": "The authors declare that they have no conflict of interest."
    },
    {
      "group": {
        "label": "Ethical approval",
        "name": "EthicsHeading"
      },
      "name": "Ethics",
      "order": 3,
      "value": "The study was evaluated by the Regional Committee for Medical and Health Research Ethics (REK Nord 2018/996) and classified as a quality-of-care study."
    }
  ],
  "author": [
    {
      "ORCID": "http://orcid.org/0000-0002-9876-576X",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Høberg-Vetti",
      "given": "Hildegunn",
      "sequence": "first"
    },
    {
      "affiliation": [],
      "family": "Ognedal",
      "given": "Elisabet",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Buisson",
      "given": "Adrien",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Vamre",
      "given": "Tone Bøe Aaman",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Ariansen",
      "given": "Sarah",
      "sequence": "additional"
    },
    {
      "ORCID": "http://orcid.org/0000-0003-0624-7066",
      "affiliation": [],
      "authenticated-orcid": false,
      "family": "Hoover",
      "given": "Jacqueline M.",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Eide",
      "given": "Geir Egil",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Houge",
      "given": "Gunnar",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Fiskerstrand",
      "given": "Torunn",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Haukanes",
      "given": "Bjørn Ivar",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Bjorvatn",
      "given": "Cathrine",
      "sequence": "additional"
    },
    {
      "affiliation": [],
      "family": "Knappskog",
      "given": "Per Morten",
      "sequence": "additional"
    }
  ],
  "container-title": [
    "European Journal of Human Genetics"
  ],
  "content-domain": {
    "crossmark-restriction": false,
    "domain": [
      "link.springer.com"
    ]
  },
  "created": {
    "date-parts": [
      [
        2020,
        3,
        20
      ]
    ],
    "date-time": "2020-03-20T17:06:58Z",
    "timestamp": 1584724018000
  },
  "deposited": {
    "date-parts": [
      [
        2023,
        5,
        20
      ]
    ],
    "date-time": "2023-05-20T21:01:41Z",
    "timestamp": 1684616501000
  },
  "indexed": {
    "date-parts": [
      [
        2024,
        3,
        22
      ]
    ],
    "date-time": "2024-03-22T22:40:28Z",
    "timestamp": 1711147228057
  },
  "is-referenced-by-count": 6,
  "issn-type": [
    {
      "type": "print",
      "value": "1018-4813"
    },
    {
      "type": "electronic",
      "value": "1476-5438"
    }
  ],
  "issue": "8",
  "issued": {
    "date-parts": [
      [
        2020,
        3,
        20
      ]
    ]
  },
  "journal-issue": {
    "issue": "8",
    "published-print": {
      "date-parts": [
        [
          2020,
          8
        ]
      ]
    }
  },
  "language": "en",
  "license": [
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "tdm",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2020,
            3,
            20
          ]
        ],
        "date-time": "2020-03-20T00:00:00Z",
        "timestamp": 1584662400000
      }
    },
    {
      "URL": "https://creativecommons.org/licenses/by/4.0",
      "content-version": "vor",
      "delay-in-days": 0,
      "start": {
        "date-parts": [
          [
            2020,
            3,
            20
          ]
        ],
        "date-time": "2020-03-20T00:00:00Z",
        "timestamp": 1584662400000
      }
    }
  ],
  "link": [
    {
      "URL": "http://www.nature.com/articles/s41431-020-0612-1.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/s41431-020-0612-1",
      "content-type": "text/html",
      "content-version": "vor",
      "intended-application": "text-mining"
    },
    {
      "URL": "http://www.nature.com/articles/s41431-020-0612-1.pdf",
      "content-type": "application/pdf",
      "content-version": "vor",
      "intended-application": "similarity-checking"
    }
  ],
  "member": "297",
  "page": "1078-1086",
  "prefix": "10.1038",
  "published": {
    "date-parts": [
      [
        2020,
        3,
        20
      ]
    ]
  },
  "published-online": {
    "date-parts": [
      [
        2020,
        3,
        20
      ]
    ]
  },
  "published-print": {
    "date-parts": [
      [
        2020,
        8
      ]
    ]
  },
  "publisher": "Springer Science and Business Media LLC",
  "reference": [
    {
      "DOI": "10.1126/science.7545954",
      "author": "Y Miki",
      "doi-asserted-by": "publisher",
      "first-page": "66",
      "journal-title": "Science",
      "key": "612_CR1",
      "unstructured": "Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994;266:66–71.",
      "volume": "266",
      "year": "1994"
    },
    {
      "DOI": "10.1038/378789a0",
      "author": "R Wooster",
      "doi-asserted-by": "publisher",
      "first-page": "789",
      "journal-title": "Nature",
      "key": "612_CR2",
      "unstructured": "Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789–92.",
      "volume": "378",
      "year": "1995"
    },
    {
      "DOI": "10.1111/cge.12291",
      "author": "WD Foulkes",
      "doi-asserted-by": "publisher",
      "first-page": "1",
      "journal-title": "Clin Genet",
      "key": "612_CR3",
      "unstructured": "Foulkes WD. BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective. Clin Genet. 2014;85:1–4.",
      "volume": "85",
      "year": "2014"
    },
    {
      "key": "612_CR4",
      "unstructured": "Norwegian Breast Cancer Group. [Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med brystkreft] Guideline. Version 13, 2019. https://helsedirektoratet.no/retningslinjer/nasjonalt-handlingsprogram-med-retningslinjer-for-diagnostikk-behandling-og-oppfolging-av-pasienter-med-brystkreft."
    },
    {
      "key": "612_CR5",
      "unstructured": "National Comprehensive Cancer Network. NCCN Guidelines - Genetic/familial High-Risk Assessment: Breast and Ovarian. Version 3. 2019. https://www.nccn.org/professionals/physician_gls/pdf/genetics_screening.pdf."
    },
    {
      "DOI": "10.1002/humu.20880",
      "author": "SE Plon",
      "doi-asserted-by": "publisher",
      "first-page": "1282",
      "journal-title": "Hum Mutat",
      "key": "612_CR6",
      "unstructured": "Plon SE, Eccles DM, Easton D, Foulkes WD, Genuardi M, Greenblatt MS, et al. Sequence variant classification and reporting: recommendations for improving the interpretation of cancer susceptibility genetic test results. Hum Mutat. 2008;29:1282–91.",
      "volume": "29",
      "year": "2008"
    },
    {
      "DOI": "10.1007/s10549-017-4602-0",
      "author": "ES Dos Santos",
      "doi-asserted-by": "publisher",
      "first-page": "311",
      "journal-title": "Breast Cancer Res Treat",
      "key": "612_CR7",
      "unstructured": "Dos Santos ES, Caputo SM, Castera L, Gendrot M, Briaux A, Breault M, et al. Assessment of the functional impact of germline BRCA1/2 variants located in non-coding regions in families with breast and/or ovarian cancer predisposition. Breast Cancer Res Treat. 2018;168:311–25.",
      "volume": "168",
      "year": "2018"
    },
    {
      "DOI": "10.1038/sj.ejhg.5200988",
      "author": "U Hamann",
      "doi-asserted-by": "publisher",
      "first-page": "464",
      "journal-title": "Eur J Hum Genet",
      "key": "612_CR8",
      "unstructured": "Hamann U, Liu X, Bungardt N, Ulmer HU, Bastert G, Sinn HP. Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany. Eur J Hum Genet. 2003;11:464–7.",
      "volume": "11",
      "year": "2003"
    },
    {
      "DOI": "10.1111/cge.12274",
      "author": "I Konstantopoulou",
      "doi-asserted-by": "publisher",
      "first-page": "36",
      "journal-title": "Clin Genet",
      "key": "612_CR9",
      "unstructured": "Konstantopoulou I, Tsitlaidou M, Fostira F, Pertesi M, Stavropoulou AV, Triantafyllidou O, et al. High prevalence of BRCA1 founder mutations in Greek breast/ovarian families. Clin Genet. 2014;85:36–42.",
      "volume": "85",
      "year": "2014"
    },
    {
      "DOI": "10.1038/ejhg.2015.196",
      "author": "H Høberg-Vetti",
      "doi-asserted-by": "publisher",
      "first-page": "881",
      "journal-title": "Eur J Hum Genet",
      "key": "612_CR10",
      "unstructured": "Høberg-Vetti H, Bjorvatn C, Fiane BE, Aas T, Woie K, Espelid H, et al. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study. Eur J Hum Genet. 2016;24:881–8.",
      "volume": "24",
      "year": "2016"
    },
    {
      "DOI": "10.1186/s13053-017-0085-6",
      "author": "C Heramb",
      "doi-asserted-by": "publisher",
      "journal-title": "Hereditary Cancer Clin Pract",
      "key": "612_CR11",
      "unstructured": "Heramb C, Wangensteen T, Grindedal EM, Ariansen SL, Lothe S, Heimdal KR, et al. BRCA1 and BRCA2 mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway. Hereditary Cancer Clin Pract. 2018;16:3.",
      "volume": "16",
      "year": "2018"
    },
    {
      "DOI": "10.1093/hmg/ddu075",
      "author": "M Colombo",
      "doi-asserted-by": "publisher",
      "first-page": "3666",
      "journal-title": "Hum Mol Genet",
      "key": "612_CR12",
      "unstructured": "Colombo M, Blok MJ, Whiley P, Santamarina M, Gutierrez-Enriquez S, Romero A, et al. Comprehensive annotation of splice junctions supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium. Hum Mol Genet. 2014;23:3666–80.",
      "volume": "23",
      "year": "2014"
    },
    {
      "DOI": "10.1186/s13058-017-0919-1",
      "author": "LC de Jong",
      "doi-asserted-by": "publisher",
      "first-page": "127",
      "journal-title": "Breast Cancer Res",
      "key": "612_CR13",
      "unstructured": "de Jong LC, Cree S, Lattimore V, Wiggins GAR, Spurdle AB, kConFab I, et al. Nanopore sequencing of full-length BRCA1 mRNA transcripts reveals co-occurrence of known exon skipping events. Breast Cancer Res. 2017;19:127.",
      "volume": "19",
      "year": "2017"
    },
    {
      "DOI": "10.1093/hmg/ddw094",
      "author": "M de la Hoya",
      "doi-asserted-by": "publisher",
      "first-page": "2256",
      "journal-title": "Hum Mol Genet",
      "key": "612_CR14",
      "unstructured": "de la Hoya M, Soukarieh O, Lopez-Perolio I, Vega A, Walker LC, van Ierland Y, et al. Combined genetic and splicing analysis of BRCA1 c.[594-2A\u003eC; 641A\u003eG] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. Hum Mol Genet. 2016;25:2256–68.",
      "volume": "25",
      "year": "2016"
    },
    {
      "DOI": "10.1038/ejhg.2017.116",
      "author": "G Davy",
      "doi-asserted-by": "publisher",
      "first-page": "1147",
      "journal-title": "Eur J Hum Genet",
      "key": "612_CR15",
      "unstructured": "Davy G, Rousselin A, Goardon N, Castera L, Harter V, Legros A, et al. Detecting splicing patterns in genes involved in hereditary breast and ovarian cancer. Eur J Hum Genet. 2017;25:1147–54.",
      "volume": "25",
      "year": "2017"
    },
    {
      "key": "612_CR16",
      "unstructured": "Evidence-based Network for the Interpretation of Germline Mutant Alleles. ENIGMA BRCA1/2 Gene Variant Classification Criteria version 2.5.1, 2017. https://enigmaconsortium.org/wp-content/uploads/2018/10/ENIGMA_Rules_2017-06-29-v2.5.1.pdf."
    },
    {
      "DOI": "10.3390/cancers11030295",
      "author": "E Gelli",
      "doi-asserted-by": "publisher",
      "first-page": "95",
      "journal-title": "Cancers (Basel)",
      "key": "612_CR17",
      "unstructured": "Gelli E, Colombo M, Pinto AM, De Vecchi G, Foglia C, Amitrano S, et al. Usefulness and Limitations of Comprehensive Characterization of mRNA Splicing Profiles in the Definition of the Clinical Relevance of BRCA1/2 Variants of Uncertain Significance. Cancers (Basel). 2019;11:295.",
      "volume": "11",
      "year": "2019"
    },
    {
      "DOI": "10.1002/humu.22101",
      "author": "C Houdayer",
      "doi-asserted-by": "publisher",
      "first-page": "1228",
      "journal-title": "Hum Mutat",
      "key": "612_CR18",
      "unstructured": "Houdayer C, Caux-Moncoutier V, Krieger S, Barrois M, Bonnet F, Bourdon V, et al. Guidelines for splicing analysis in molecular diagnosis derived from a set of 327 combined in silico/in vitro studies on BRCA1 and BRCA2 variants. Hum Mutat. 2012;33:1228–38.",
      "volume": "33",
      "year": "2012"
    },
    {
      "DOI": "10.1002/humu.22388",
      "author": "LC Walker",
      "doi-asserted-by": "publisher",
      "first-page": "1424",
      "journal-title": "Hum Mutat",
      "key": "612_CR19",
      "unstructured": "Walker LC, Whiley PJ, Houdayer C, Hansen TV, Vega A, Santamarina M, et al. Evaluation of a 5-tier scheme proposed for classification of sequence variants using bioinformatic and splicing assay data: inter-reviewer variability and promotion of minimum reporting guidelines. Hum Mutat. 2013;34:1424–31.",
      "volume": "34",
      "year": "2013"
    },
    {
      "DOI": "10.1136/jmedgenet-2017-104584",
      "author": "DG Evans",
      "doi-asserted-by": "publisher",
      "first-page": "674",
      "journal-title": "J Med Genet",
      "key": "612_CR20",
      "unstructured": "Evans DG, Harkness EF, Plaskocinska I, Wallace AJ, Clancy T, Woodward ER, et al. Pathology update to the Manchester Scoring System based on testing in over 4000 families. J Med Genet. 2017;54:674–81.",
      "volume": "54",
      "year": "2017"
    },
    {
      "DOI": "10.1186/s13059-016-0881-8",
      "author": "A Conesa",
      "doi-asserted-by": "publisher",
      "journal-title": "Genome Biol",
      "key": "612_CR21",
      "unstructured": "Conesa A, Madrigal P, Tarazona S, Gomez-Cabrero D, Cervera A, McPherson A, et al. A survey of best practices for RNA-seq data analysis. Genome Biol. 2016;17:13.",
      "volume": "17",
      "year": "2016"
    },
    {
      "key": "612_CR22",
      "unstructured": "Cancer Registry of Norway. Cancer in Norway 2017 - Cancer incidence, mortality, survival and prevalence in Norway. Oslo: Cancer Registry of Norway; 2018."
    },
    {
      "DOI": "10.1001/jama.2017.7112",
      "author": "KB Kuchenbaecker",
      "doi-asserted-by": "publisher",
      "first-page": "2402",
      "journal-title": "JAMA",
      "key": "612_CR23",
      "unstructured": "Kuchenbaecker KB, Hopper JL, Barnes DR, Phillips KA, Mooij TM, Roos-Blom MJ, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA. 2017;317:2402–16.",
      "volume": "317",
      "year": "2017"
    },
    {
      "DOI": "10.1002/ijc.31841",
      "author": "J Li",
      "doi-asserted-by": "publisher",
      "first-page": "1195",
      "journal-title": "Int J Cancer",
      "key": "612_CR24",
      "unstructured": "Li J, Wen WX, Eklund M, Kvist A, Eriksson M, Christensen HN, et al. Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort. International journal of cancer. Int J Cancer. 2019;144:1195–204.",
      "volume": "144",
      "year": "2019"
    },
    {
      "DOI": "10.1126/science.1209909",
      "author": "R Shakya",
      "doi-asserted-by": "publisher",
      "first-page": "525",
      "journal-title": "Science",
      "key": "612_CR25",
      "unstructured": "Shakya R, Reid LJ, Reczek CR, Cole F, Egli D, Lin CS, et al. BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its E3 ligase activity. Science. 2011;334:525–8.",
      "volume": "334",
      "year": "2011"
    },
    {
      "DOI": "10.1002/humu.9176",
      "author": "B Campos",
      "doi-asserted-by": "publisher",
      "first-page": "337",
      "journal-title": "Hum Mutat",
      "key": "612_CR26",
      "unstructured": "Campos B, Diez O, Domenech M, Baena M, Balmana J, Sanz J, et al. RNA analysis of eight BRCA1 and BRCA2 unclassified variants identified in breast/ovarian cancer families from Spain. Hum Mutat. 2003;22:337.",
      "volume": "22",
      "year": "2003"
    },
    {
      "DOI": "10.1186/s13053-019-0113-9",
      "author": "T Wangensteen",
      "doi-asserted-by": "publisher",
      "journal-title": "Hered Cancer Clin Pract",
      "key": "612_CR27",
      "unstructured": "Wangensteen T, Felde CN, Ahmed D, Maehle L, Ariansen SL. Diagnostic mRNA splicing assay for variants in BRCA1 and BRCA2 identified two novel pathogenic splicing aberrations. Hered Cancer Clin Pract. 2019;17:14.",
      "volume": "17",
      "year": "2019"
    },
    {
      "DOI": "10.1007/s10549-017-4142-7",
      "author": "B Park",
      "doi-asserted-by": "publisher",
      "first-page": "139",
      "journal-title": "Breast Cancer Res Treat",
      "key": "612_CR28",
      "unstructured": "Park B, Sohn JY, Yoon KA, Lee KS, Cho EH, Lim MC, et al. Characteristics of BRCA1/2 mutations carriers including large genomic rearrangements in high risk breast cancer patients. Breast Cancer Res Treat. 2017;163:139–50.",
      "volume": "163",
      "year": "2017"
    },
    {
      "DOI": "10.1136/jmg.2009.074047",
      "author": "P Gaildrat",
      "doi-asserted-by": "publisher",
      "first-page": "398",
      "journal-title": "J Med Genet",
      "key": "612_CR29",
      "unstructured": "Gaildrat P, Krieger S, Thery JC, Killian A, Rousselin A, Berthet P, et al. The BRCA1 c.5434C-\u003eG (p.Pro1812Ala) variant induces a deleterious exon 23 skipping by affecting exonic splicing regulatory elements. J Med Genet. 2010;47:398–403.",
      "volume": "47",
      "year": "2010"
    },
    {
      "author": "N Rave-Harel",
      "first-page": "87",
      "journal-title": "Am J Hum Genet",
      "key": "612_CR30",
      "unstructured": "Rave-Harel N, Kerem E, Nissim-Rafinia M, Madjar I, Goshen R, Augarten A, et al. The molecular basis of partial penetrance of splicing mutations in cystic fibrosis. Am J Hum Genet. 1997;60:87–94.",
      "volume": "60",
      "year": "1997"
    },
    {
      "DOI": "10.1002/humu.21500",
      "author": "J Fernandez-Rodriguez",
      "doi-asserted-by": "publisher",
      "first-page": "705",
      "journal-title": "Hum Mutat",
      "key": "612_CR31",
      "unstructured": "Fernandez-Rodriguez J, Castellsague J, Benito L, Benavente Y, Capella G, Blanco I, et al. A mild neurofibromatosis type 1 phenotype produced by the combination of the benign nature of a leaky NF1-splice mutation and the presence of a complex mosaicism. Hum Mutat. 2011;32:705–9.",
      "volume": "32",
      "year": "2011"
    },
    {
      "DOI": "10.1002/humu.9305",
      "author": "F Sanchez-Sanchez",
      "doi-asserted-by": "publisher",
      "first-page": "223",
      "journal-title": "Hum Mutat",
      "key": "612_CR32",
      "unstructured": "Sanchez-Sanchez F, Kruetzfeldt M, Najera C, Mittnacht S. A novel constitutional mutation affecting splicing of retinoblastoma tumor suppressor gene intron 23 causes partial loss of pRB activity. Hum Mutat. 2005;25:223.",
      "volume": "25",
      "year": "2005"
    },
    {
      "DOI": "10.1136/jmedgenet-2017-104560",
      "author": "S Moghadasi",
      "doi-asserted-by": "publisher",
      "first-page": "15",
      "journal-title": "J Med Genet",
      "key": "612_CR33",
      "unstructured": "Moghadasi S, Meeks HD, Vreeswijk MP, Janssen LA, Borg A, Ehrencrona H, et al. The BRCA1 c. 5096G\u003eA p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. J Med Genet. 2018;55:15–20.",
      "volume": "55",
      "year": "2018"
    }
  ],
  "reference-count": 33,
  "references-count": 33,
  "resource": {
    "primary": {
      "URL": "https://www.nature.com/articles/s41431-020-0612-1"
    }
  },
  "score": 0,
  "short-container-title": [
    "Eur J Hum Genet"
  ],
  "source": "Crossref",
  "title": [
    "The intronic BRCA1 c.5407-25T\u0026gt;A variant causing partly skipping of exon 23—a likely pathogenic variant with reduced penetrance?"
  ],
  "type": "journal-article",
  "update-policy": "http://dx.doi.org/10.1007/springer_crossmark_policy",
  "volume": "28"
}